- Home
- CHRS vs TEAF Comparison
CHRS vs TEAF Comparison
Compare CHRS & TEAF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CHRS
- TEAF
- Stock Information
- Founded
- CHRS 2010
- TEAF 2017
- Country
- CHRS United States
- TEAF United States
- Employees
- CHRS N/A
- TEAF N/A
- Industry
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- TEAF Trusts Except Educational Religious and Charitable
- Sector
- CHRS Health Care
- TEAF Finance
- Exchange
- CHRS Nasdaq
- TEAF Nasdaq
- Market Cap
- CHRS 84.2M
- TEAF 163.0M
- IPO Year
- CHRS 2014
- TEAF N/A
- Fundamental
- Price
- CHRS $0.90
- TEAF $12.16
- Analyst Decision
- CHRS Buy
- TEAF
- Analyst Count
- CHRS 3
- TEAF 0
- Target Price
- CHRS $4.68
- TEAF N/A
- AVG Volume (30 Days)
- CHRS 1.2M
- TEAF 56.1K
- Earning Date
- CHRS 08-07-2025
- TEAF 01-01-0001
- Dividend Yield
- CHRS N/A
- TEAF 9.20%
- EPS Growth
- CHRS N/A
- TEAF N/A
- EPS
- CHRS N/A
- TEAF N/A
- Revenue
- CHRS $272,251,000.00
- TEAF N/A
- Revenue This Year
- CHRS N/A
- TEAF N/A
- Revenue Next Year
- CHRS $106.56
- TEAF N/A
- P/E Ratio
- CHRS N/A
- TEAF N/A
- Revenue Growth
- CHRS 19.87
- TEAF N/A
- 52 Week Low
- CHRS $0.66
- TEAF $11.11
- 52 Week High
- CHRS $2.43
- TEAF $13.30
- Technical
- Relative Strength Index (RSI)
- CHRS 59.04
- TEAF 61.64
- Support Level
- CHRS $0.73
- TEAF $11.99
- Resistance Level
- CHRS $0.82
- TEAF $12.31
- Average True Range (ATR)
- CHRS 0.04
- TEAF 0.13
- MACD
- CHRS 0.02
- TEAF -0.00
- Stochastic Oscillator
- CHRS 88.02
- TEAF 67.88
About CHRS Coherus BioSciences Inc.
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its strategy is to expand the use of LOQTORZI in NPC and advance the development of new indications for LOQTORZI in combination with both its pipeline candidates as well as its industry partners, driving synergies from proprietary combinations, including first-in-class anticancer agents. Its portfolio includes LOQTORZI, CHS-114, and Casdozokitug.
About TEAF Ecofin Sustainable and Social Impact Term Fund
Tortoise Essential Assets Income Term is a USA-based non-diversified, closed-end management investment company. Its investment objective is to provide common shareholders with a high level of total return with an emphasis on current distributions.